Drug combo aims to shrink returning oral tumors before surgery
NCT ID NCT06448026
First seen Nov 15, 2025 · Last updated Jun 22, 2026 · Updated 24 times
Summary
This phase 2 trial tests whether giving two drugs, cemiplimab and cetuximab, before salvage surgery can help control recurrent oral cavity squamous cell carcinoma. The study will enroll 17 adults whose cancer has returned at least 3 months after prior treatment. Researchers will monitor safety and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cemiplimab and cetuximab (drugs given by IV)
What this could lead to
If it works, this could point toward a way to shrink recurrent oral cancers before surgery, possibly improving outcomes.
What could go wrong
This is a very small, early-phase trial with only 17 people. The combination may not work or could cause serious side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.